NCT05470101View on ClinicalTrials.gov

A PET Study Following a Single Oral Dose of ITI-333 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

July 26, 2022

Primary Completion Date

May 3, 2023

Study Completion Date

May 3, 2023

Conditions
Healthy Volunteers
Interventions
DRUG

ITI-333

ITI-333 oral solution

Trial Locations (2)

63110

Clinical Site 1, St Louis

63141

Clinical Site 2, Creve Coeur

Sponsors
All Listed Sponsors
collaborator

National Institute on Drug Abuse (NIDA)

NIH

lead

Intra-Cellular Therapies, Inc.

INDUSTRY

NCT05470101 - A PET Study Following a Single Oral Dose of ITI-333 in Healthy Subjects | Biotech Hunter | Biotech Hunter